VC style returns on 'unsexy' public health bets? Gates-backed Adjuvant Capital gathers $300M to mend a 'failure of imagination'

Amber Tong

Glenn Rockman was summoned, about three years into a senior role on JP Morgan’s non-profit investment banking team, to a special assignment reviewing a pipeline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

VC style returns on 'unsexy' public health bets? Gates-backed Adjuvant Capital gathers $300M to mend a 'failure of imagination'

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

VC style re­turns on 'un­sexy' pub­lic health bets? Gates-backed Ad­ju­vant Cap­i­tal gath­ers $300M to mend a 'fail­ure of imag­i­na­tion'

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

VC style returns on 'unsexy' public health bets? Gates-backed Adjuvant Capital gathers $300M to mend a 'failure of imagination'